| 1991 |
Ross PD, Davis JW, Epstein RS, Wasnich RD. Pre-existing fractures and bone mass predict vertebral fracture incidence in women. Ann Intern Med. June 1, 1991;114(11):919-923. |
54 |
51 |
| 1996 |
Wasnich RD. Vertebral fracture epidemiology. Bone. March 1996;18(3)(suppl 1):S179-S183. |
11 |
11 |
| 1990 |
Ross PD, Davis JW, Vogel JM, Wasnich RD. A critical review of bone mass and the risk of fractures in osteoporosis. Calcif Tiss Int. March 1990;46(3):149-161. |
33 |
32 |
| 2002 |
Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. April 2002;87(4):1586-1592. |
23 |
21 |
| 1990 |
Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, Licata AA, Ross P, Woodson GC III, Yanover MJ, Mysiw WJ, Kohse L, Rao MB, Steiger P, Richmond B, Chesnut CH III. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. NEJM. July 12, 1990;323(2):73-79. |
41 |
29 |
| 2001 |
McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Wasnich RD, Greenwald M, Kaufman J-M, Chesnut CH, Reginster J-Y; Hip Intervention Program Study Group. Effect of risedronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. NEJM. February 1, 2001;344(5):333-340. |
73 |
56 |
| 1993 |
Ross PD, Genant HK, Davis JW, Miller PD, Wasnich RD. Predicting vertebral fracture incidence from prevalent fractures and bone density among non-black, osteoporotic women. Osteoporos Int. May 1993;3(3):120-126. |
19 |
17 |